IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

TRANSDERMAL DRUG DELIVERY SYSTEM

Pooja G. Barokar, Sakshi Muthe, Suvarna Kapadi, Nikita Mahale.

UG Student, Department of B. Pharmacy Pravara College Of Pharmacy(For Women,s) Chincholi, Nashik,Maharashtra.

Mrs. Sayli Chothave,

Assistant Professor, Department of B Pharmacy Pravara College Of Pharmacy (For Women,s) Chincholi, Nashik.

ABSTRACT:

A promising and non-invasive method for the gradual and regulated release of medicinal substances through the skin into the bloodstream is the use of transdermal drug delivery systems (TDDS). With a number of benefits over traditional oral and parenteral routes, including better patient compliance, avoiding first-pass hepatic metabolism, lowering the frequency of doses, and maintaining constant plasma drug concentrations, TDDS development has advanced dramatically in recent decades. However, only strong medications with advantageous physicochemical characteristics may be applied transdermally due to the stratum corneum, the skin's outermost layer, which acts as a significant barrier to drug penetration. The justification for transdermal delivery, the optimal characteristics of medications and penetration enhancers, and the system's benefits and drawbacks are all covered in this paper. The key ingredients of TDDS, such as polymers, adhesives, backing laminates, and release liners, are described together with a variety of preparation procedures, such as asymmetric membrane, circular Teflon mold, mercury substrate, and proliposome approaches. Transdermal patch types (single-layer, multi-layer, reservoir, matrix, and vapor patches) and their assessment criteria, such as thickness, drug content, adhesion, moisture content, and mechanical properties, are also highlighted in the review. The elements influencing transdermal absorption, including skin condition, age, hydration, and environmental impacts, are described, along with commercially available transdermal products like nicotine, fentanyl, clonidine, and hormone patches. All things considered, TDDS is still developing as a crucial technology in contemporary pharmaceutics, offering a practical and efficient platform for systemic therapy with improved safety and effectiveness.

KEYWORDS: Transdermal drug delivery system, controlled release, skin permeability,

INTRODUCTION

The innovations in the field of drug delivery are occurring at a much more rapid rate compared to the last two decades. Better compliance and efficacy are inseparable features of new drug delivery systems. [1,2] More revolutionary has been the strategy to look for newer sites on the body to introduce therapeutics. One of these strategies, transdermal drug delivery, utilizes human skin as a point of entry for systemic administration of drug molecules. [3] Transdermal drug delivery system (TDDS) is a system under the category of controlled drug delivery, where the objective is to deliver the drug across the skin at a predetermined and controlled rate. TDDS are adhesive drug-loaded devices of specified surface area that deliver a specified quantity of drug to the intact skin surface at a rate predetermined to achieve the systemic circulation. [4,5] Transdermal delivery has a head start over injectables and oral administration by enhancing patient compliance and preventing first-pass metabolism, respectively. [6,7] Transdermal route has competed with oral treatment as the most successful new research field in drug delivery, since oral treatment entails achievement and sustenance of

drug concentration in the body to a therapeutically effective level by intrusion of a fixed amount at a fixed interval of time, owing to which the drug level in the body exhibits a peak and trough pattern, resulting in an increased likelihood of side effects or failure of therapy; excessive amount of drug is lost in the vicinity of the target organ and very close monitoring is needed to oversee therapy to avoid overdose. The oral route limitations can be surpassed and advantages of intravenous drug infusion like to circumvent hepatic "first pass" hepatic elimination (HEPE) to provide constant prolonged and therapeutic effective drug levels in the body can be replicated, without its possible dangers, by transdermal drug delivery through intact skin. [8-10] Table 1 depicts the merits and demerits of delivering drug through the skin for systemic therapy.

RATIONALE

The skin provides such a good barrier to molecular transport, the rationale for this delivery strategy must be clearly identified. There are numerous occasions when the most convenient of drug intake routes (the oral route) is not possible thus alternative routes must be found. Even though intravenous introduction of the medicament circumvents many of these deficiencies (such as gastrointestinal tract (GIT) and hepatic metabolism), its invasiveness (especially for chronic administration) has motivated the quest for alternative approaches and few anatomical orifices have not been explored for their potential as alternative drug delivery routes. The use of TDD technology must be therapeutically warranted. Drugs with high oral bioavailability and sporadic dosing regimens well tolerated by patients do not deserve such interventions. Likewise, transdermal delivery is not a tool to provide for quick bolus-type drug inputs, but it is typically intended to provide slow, sustained drug delivery over long periods of time and, as a consequence, tolerance-inducing drugs or those (e.g., hormones) that need chrono pharmacological control are, at least to date, not indicated. There is still, however, a large number of drugs for which TDD would be desirable but currently impossible. The nature of the stratum corneum (SC) is essentially the solution to this problem. The high diffusional resistance provided by the membrane results in the amount of daily drug dose that can be delivered systematically via a reasonable 'patch-size' area being in the < 10 mg range [11]

IDEAL PROPERTIES

Ideally, penetration enhancers reversibly decrease the barrier resistance of the stratum corneum without harming viable cells. Some of the preferable properties for penetration enhancers operating in the skin have been presented as:

• They should be non-toxic, non-irritating and non-allergenic
• They would ideally act quickly; the activity and duration of action should be predictable and reproducible.
• They must be pharmacologically inactive in the body.
• The penetration enhancers must act unidirectionally, i.e., they must bring therapeutic agents into the body while not causing loss of endogenous materials from the body.
• On removal from the skin, barrier properties must reverse rapidly and completely to normal.
• They must be cosmetically acceptable with a suitable skin feel. [12,13]

ADVANTAGES:

• Hepatic first pass metabolism, salivary metabolism and intestinal metabolism are avoided.
• Easy of usage makes it possible for patient to self-administer these systems.
• In case of an emergency, removing the patch at any point of time during therapy can Impact factor.
• Since the composition of skin structurally and biologically is the some in almost all humans, there is minimal inter and intra patient variation.
• Drugs exhibiting gastrointestinal irritation and absorption may be appropriately delivered through skin.
. Non-invasive, continuous infusion is possible for drugs with short biological half life which otherwise need frequent dosing**.**
. As there is less frequency of dosing there is increased patient compliance**.**
. Therapeutic failures related to irregularities in dosing with conventional therapy can be eliminated**.**
.Side effects are reduced because of a constant and optimal blood concentration time profile.
• Parenteral therapy risks, pain and discomfort are avoided. Release is longer than oral sustained drug release systems.

• Sometimes the maintenance of the drug concentration in the bio phase is not desirable; Thus transdermal systems are appropriate in this instance.
• Daily dose of medication needed is less than that with traditional therapy.
• Drug release is of a type that there is a prolonged and consistent interval of activity.

DISADVANTAGES:
• There is risk of irritation of the skin because of the one or more of formulation components.
• Attachment of drug to skin can lead to dose dumping.
• It is usable only for chronic diseases in which drug therapy is intended for a prolonged period of time such as hypertension, angina and diabetes.
• Lag time is unpredictable and may range from hours to days for different drug candidates.
• Cutaneous metabolism will influence therapeutic performance of the system. Transdermal therapy is possible with some potent drugs only.
• Transdermal treatment is not possible for ionic drugs.
• It is unable to provide drug in pulsatile manner [14].

PREPARATION METIOD OF TDDS

Asymmetric TPX membrane method: -

patch can be prepared from a concave of diameter 1 cm heat sealable polyester film will serve as the backing membrane. Drug sample is filled into concave membrane, covered with TPX {poly- (4-methyl-1-pentene)} asymmetric membrane, and sealed by an adhesive.

Circular Teflon mould method: - Solutions with polymers in different ratios are applied in an organic solvent. Amount of drug calculated is dissolved in half the amount of same organic solvent. Different concentrations of enhancers are dissolved in the other half of organic solvent and then added. Di-N butyl phthalate is added as plasticizer into drug polymer solution. Total contents are mixed for 12 h and cast into round Teflon mould. The moulds are laid on a level surface and covered with inverted funnel to regulate solvent evaporation in a laminar flow hood model having an air velocity of 0.5 m/s. The solvent is left to evaporate for 24 h. Dried films are kept under another 24 h at 25±0.5°C in a desiccators filled with silica gel prior to evaluation to exclude aging effects.

Mercury substrate method: - Drug is dissolved in plasticizer and polymer solution. The above solution should be stirred for 10-15 min to form a homogenous dispersion and added to a levelled mercury surface, covered with inverted funnel to regulate solvent evaporation.

" IPM membranes" method-

In this process, medicine is dispersed in water and propylene glycol admixture containing carbomer 940 polymer and stirred for 12 h in glamorous stirrer. The dissipation is to be annulled and made thick bye the addition of triethanolamine. Buffer pH 7.4 can be used in order to gain result gel, if the medicine solubility in waterless result is veritably poor. The formed gel will be incorporated in the IPM membrane**.**

"EVAC membranes" method: - In order to prepare the target transdermal therapeutic system, 1% Carbopol reservoir gel, polyethylene (PE), ethylene vinyl acetate copolymer (EVAC) membranes may be utilized as rate control membranes. When the drug is insoluble in water, propylene glycol is employed for gel preparation. Drug is dissolved in propylene glycol; Carbopol resin will be mixed with the above solution and neutralized by using 5% w/w solution of sodium hydroxide. The medication (in gel state) is applied over a sheet of backing layer covering the area to be covered. A rate controlling membrane is applied over the gel and edges are sealed with heat to achieve a leak proof device.

Aluminium backed tenacious film system Transdermal medicine delivery system can form unstable matrices if the cure of lading is above 10 aluminium backed tenacious film system is a accessible bone. Chloroform is choice of detergent, since maturity of medicines as well as bonds are answerable in chloroform. medicine is dissolved in chloroform and tenacious material will be added to medicine result and dissolved. A especially made aluminium former is lined with aluminium antipode and the ends blanked off with tightly fitting cork blocks.

Preparation of TDDS by proliposomes using- The proliposomes are prepared by carrier system with film deposit fashion. From the former reference medicine and lecithin in the proportion of 0.12.0 can be employed as an optimized one. The proliposomes are prepared by taking 5 mg mannitol greasepaint in a 100 ml round bottom beaker which is maintained at 60- 70 ° c temperature and the beaker is spun at 80- 90 rpm and dried the mannitol at vacuum for 30 min. Upon drying, the water bath temperature is set to 20- 30 °C. medicine and lecithin are dissolved in an applicable organic detergent admixture; a 0.5 ml aliquot of the organic result is placed into the round bottomed beaker at 37 °C, after complete drying alternate aliquot (0.5 ml) of result is to be added. After the final lading, the beaker of proliposomes are joined in a lyophilyzer and also medicine loaded mannitol maquillages proliposomes) are put in a desiccator overnight and also settled through 100 mesh. The greasepaint collected is poured into a glass bottle and stored at the freezing temperature until characterization. Free film system-Free film of cellulose acetate is prepared by casting on mercury face. A polymer 2 w/ w result is to be prepared by employing chloroform. Plasticizers are to be added with a 40 w/ w of polymer weight. Five ml of polymer result was poured in a glass ring which is deposited over the mercury face in a glass petri dish. The rate of evaporation of the detergent is regulated by putting an reversed channel over the petri dish. The film information is recorded by measuring the mercury face after total evaporation of the detergent. The dry film will be separated out and kept between the wastes of wax paper in desiccator until the time of use. Free flicks of colourful consistence can be prepared by varying the volume of the polymer result (15,16).

BESIC COMPONENTS:

Polymer matrix/ medicine force: Polymers form the core of TDDS, which regulate medicine release from the device. Polymer matrix can be formulated by dissipation of medicine in liquid or solids state synthetic polymer base. Polymers employed in TDDS need to have biocompatibility and chemical comity with the medicine and the other factors of the system like penetration enhancers and PSAs. In addition to that should deliver a medicine constantly and effectively across the products intended shelf life and should be of safe status. enterprises operating in the area of transdermal delivery focus on a limited number of picky polymeric systems. For case, Alza Corporation primarily focuses on ethylene vinyl acetate (EVA) copolymers or microporous polypropylene and Searle Pharmacia focuses on silicon rubber. Likewise Colorcon, UK employs HPMC for medication of matrix for propranolol transdermal delivery and Sigma employs ethyl cellulose in the medication of isosorbide dinitrate matrix. Polymers employed in TDDS can be grouped as**, Natural Polymers** e.g. derivations of cellulose, zein, gelatin, shellac, waxes, epoxies, natural rubber and chitosan etc. Synthetic **Elastomers** e.g. polybutadiene, hydrin rubber, polyisobutylene, silicon rubber, nitrile, acrylonitrile, neoprene, butyl rubber etc. **Synthetic Polymers** e.g. polyvinyl alcohol, polyvinylchloride, polyethylene, polypropylene, polyacrylate, polyamide, polyurea, polyvinylpyrrolidone, polymethylmethacrylate etc. The polymers similar as cross linked polyethylene glycol, neudragits, ethyl cellulose, polyvinylpyrrolidone and hydroxy propyl methylcellulose are matrix formers in TDDS. Other polymers similar as EVA, silicon rubber and polyurethane act as rate controlling membrane.

Medicine:

The transdermal delivery is a veritably promising option for the medicines enjoying suitable pharmacology and physical chemistry. Transdermal patches give important to the medicines which are subordinated to first pass metabolism to a great extent, medicines with narrow remedial window, or short halflife medicines that results in non-compliance because of the need to constantly administer. The most critical demand of TDDS is that the medicine must have the right combination of physicochemical and natural features for transdermal medicine delivery. It has been widely accepted that ideal medicine campaigners for un resistant tenacious transdermal patches should be non-ionic, of low molecular weight (lower than 500 Daltons), retain good oil painting and waterless solubility (log P between 1- 3), low melting point (lower than 200 °C) and are active (cure in mg per day). Table 1 lists the medicines available for transdermal delivery. piecemeal from medicines similar as rivastigmine for Alzheimer and Parkinson madness, rotigotine for Parkinson, methylphenidate for attention deficiency hyperactive complaint and selegiline for depression are recently approved as TDDS.

Saturation Enhancers:

Three routes of medicine penetration through the skin are proposed polar, non-polar, and polar/non-polar. Enhancers work by modifying one of these routes. The secret to modifying the polar route is to induce protein conformational change or solvent lump. The secret to modifying the nonpolar route is to modify the severity of the lipid structure and fluidize the crystalline pathway (this greatly increases prolixity). The enhancers of adipose acids enhance the fluidity of the lipid element of the Stratum Corneum. Certain enhancers (double vehicles) influence both polar and nonpolar pathways by modifying the multi laminate pathway for penetrants. Enhancers may enhance the medicine diffusivity in the Stratum Corneum (SC) by dissolving skin lipids or by denaturing skin proteins. The nature of the enhancer used plays a significant impact on the design and development of the product. The success of dermatological medicine products that are intended for systemic medicine delivery, similar as the transdermal, depends on the capability of the medicine to access through the skin in sufficient amounts to achieve its asked remedial effect. The styles employed for modifying the hedge parcels of the SC to enhance the medicine penetration (and immersion) via the skin can be classified as (1) Chemical and (2) physical approaches to improvement

Chemical Enhancers

Chemicals that enhance topically administered medicine penetration are generally called accelerants, immersion promoters, or penetration enhancers. Chemical enhancer Transdermal Drug Delivery System Enhancing medicine permeability through the skin by converting reversible damage to the SC. Adding (and optimizing) thermodynamic exertion of the medicine when performing as co detergent. adding the partition measure of the medicine to promote its release from the vehicle into the skin. Conditioning the SC to promote medicine prolixity. Promoting penetration and establish medicine force in the SC.

Physical enhancers

The iontophoresis and ultra sound (also known as phonophoresis or sonophoresis) ways are exemplifications of physical styles of improvement that have set up operation in enhancing bond with not lesser than applied cutlet pressure, be largely and permanently tachy, and have a high holding force. also, it should be removable from the smooth face without leaving a residue. Polyacrylates, polyisobutylene and silicon grounded bonds are extensively used in TDDSs. The selection of an glue is grounded on multitudinous factors, including the patch design percutaneous penetration (and immersion) of several remedial agents.

Pressure sensitive bonds

PSB is a material that assists in creating a close contact between transdermal system and the skin face. It must and medicine expression. For matrix systems with a supplemental glue, an incidental contact between the tenacious and the medicine and penetration enhancer should n't beget insecurity of the medicine, penetration enhancer or the glue. For force systems which contain a face glue, the diffusing medicine should n't impact the glue. For medicine- in- glue matrix systems, the choice will be made grounded on how snappily the medicine and the penetration enhancer will diffuse through the glue. immaculately, PSA should be physic chemically and biologically compatible and should n't impact medicine release.

Backing Laminate

During the design of a backing sub caste, the aspect of chemical resistance of the material is most significant. Excipients comity also needs to be taken in to account since the extended stay between the excipients and the backing sub caste may affect in the filtering out of the complements from the backing sub caste or may beget the prolixity of excipients, medicine or penetration enhancer through the sub caste. nevertheless, an too important emphasis on chemical resistance can affect in severity and inordinate occlusive to humidity vapor and air, making patches lift and potentially irritate the skin under extended wear and tear. The most comfortable supporting backing will be the one showing smallest modulus or loftiest inflexibility, excellent oxygen transmission and a high humidity vapor transmission rate. Samples of some accoutrements used as backings are vinyl, polyethylene and polyester flicks.

Release Liner

During storehouse, the patch is defended by a hedge liner that's stripped off and released just before the patch is applied to the skin. It's therefore considered a element of the primary packaging material and not an integral part of the lozenge form for the delivery of the medicine. But since the liner is in close contact with the delivery system, it must cleave to certain conditions concerning chemical idleness and penetration to the medicine, penetration enhancer and water. generally, release liner consists of a base sub caste which is either non- occlusive (e.g. paper fabric) or occlusive (e.g. polyethylene, polyvinylchloride) and release coating sub

caste conforming of silicon or teflon. Other accoutrements for use in TDDS release liner are polyester antipode and metallized laminates.

Other excipients

Detergents like chloroform, methanol, acetone, isopropanol and dichloromethane are used to prepare medicine force. Pl Plasticizers like dibutylpthalate, triethyl citrate, polyethylene glycol and propylene glycol are also added to conduct malleability to the transdermal patch (17,18,19,20,21).

TYPES

Single- sub caste medicine- in- Adhesive The tenacious sub caste of this system also carries the medicine. In this form of patch the tenacious sub caste not only holds the different layers together, as well as the whole system to the skin, but is also used for the releasing of the medicine. The tenacious sub caste is covered with a temporary liner and a backing (22).

Multi-layer medicine- in- Adhesive

The multi-layer medicine- in tenacious patch is similar to the single- sub caste system in that both tenacious layers are also involved in the releasing of the medicine. The multi-layer system is different still in that it incorporates an fresh sub caste of medicine- in- glue, generally being divided by a membrane (although not in all cases). This patch also consists of a temporary liner- sub caste and a endless backing (23)

Reservoir

The force transdermal system possesses a distinct medicine sub caste. The medicine sub caste is a liquid cube with a medicine result or suspense separated by the tenacious sub caste. This patch is further supported by the backing sub caste. In this system type the rate of release is zero order (24).

Matrix

The Matrix system possesses a medicine sub caste of a circumfluous matrix with a medicine result or suspense. The tenacious sub caste in the patch encircles the medicine sub caste incompletely covering it (25).

Vapour Patch

In the patch of this kind the tenacious sub caste is used to not only hold different layers together but also to release vapour. The vapour patches are recently introduced on the request and they release essential canvases for over to 6 hours. The vapours patches release essential canvases and are employed in decongestion cases primarily. Other vapour patches that live on the request include regulator vapour patches that enhance the quality of sleep. Vapour patches reducing the number of cigarettes one smokes within a month are also present on the request (26).

EVALUATION PARAMETERS

1. **Interaction studies**

   Excipients are part of nearly all of the pharmaceutical lozenge forms. The stability of a expression among other aspects is reliant on the comity of the medicine with the excipients. The medicine and excipients need to be compatible with each other in order to yield a product that's stable, hence it's obligatory to identify any probable physical or chemical commerce since it may impact the stability and bioavailability of the medicine. The comity studies will be critical in expression development if excipients are new and not preliminarily used in phrasings with the active component. Interaction studies are routinely performed in Thermal analysis, FT- IR, UV and chromatographic styles by comparing their physicochemical characters similar as assay, melting endotherms, characteristic surge figures, immersion maxes etc.

2. Consistence of the patch

The consistence of the medicine loaded patch is measured in different points by using a digital micro cadence and determines the average consistence and standard divagation for the same to insure the consistence of the set patch.

3. Weight uniformity

The set patches are to be dried at 60 ° c for 4 hrs before testing. A specified area of patch is to be cut in colourful corridor of the patch and counted in digital balance. Average weight and standard divagation values are to be set up from the individual weights.

4. Folding abidance

A piece of specific are is to be cut unevenly and folded constantly at the same spot until it broke. The number of crowds the film can be folded at the same position without breaking handed the value of the folding abidance.

5. Chance humidity content

Individual flicks prepared are to be counted and to be stored in a desiccator with fused calcium chloride at room temperature for 24 hrs. At 24 hrs, the flicks are to be revisited and calculate the chance humidity content using the following formula.

Chance humidity content = (original weight-Final weight/ Final weight) × 100.

6. Chance humidity uptake

The counted flicks shall be placed in a desiccator at room temperature for 24 hrs containing impregnated result of potassium chloride to give 84 RH. The flicks after 24 hrs are to be revisited and calculate the chance humidity immersion using the following mentioned formula.

Chance humidity uptake = (Final weight-original weight/ original weight) × 100.

7. Water vapour permeability (WVP) test

Water vapour permeability is measured by froth dressing fashion the forced air roaster is replaced with natural air rotation roaster. WVP can be calculated by using the ensuing expression

WVP = W/ A

Where, WVP in terms of gm/ m ² per 24 hrs, W is the volume of vapour transmitted through the patch in gm/ 24 hrs and A is the face area of the exposure samples in terms of m.

8. medicine content

A certain area of patch is to be dissolved in an applicable detergent in definite volume. Also the result is to be filtered through a sludge medium and analysis the medicine contain with the applicable system (UV or HPLC fashion). Each value is average of three different samples.

9. Uniformity of lozenge unit test

A precisely counted quantum of the patch is to be finely cut and moved to a specific volume volumetric beaker, solubilized in an applicable detergent and sonicate till medicine is completely uprooted from the patch and made up to the mark with same. The result therefore attained was left to settle for roughly an hour and the supernatant was meetly adulterated to give the asked attention with applicable detergent. The result was filtered through 0.2 m membrane sludge and anatomized by applicable logical system (UV or HPLC) and the medicine content per piece will be determined.

10. Examination of Polariscope

This test shall be carried out to dissect the medicine chargers from patch through polariscope. A definite face area of the test piece is to be placed on object slide and look for the medicines chargers to identify whether the medicine is set up in crystalline form or unformed form in the patch.

11. Shear Adhesion test

The test to be conducted for the determination of the cohesive strength of an tenacious polymer. It may be affected by molecular weight, extent of crosslinking and polymer composition, type and position of tackifier introduced. An tenacious tape recording is stuck on a pristine sword plate; a given weight is attached at the tape recording, to impact it pulling in a direction parallel to the plate. Shear adhesion strength is measured by recording the time it requires to remove the tape recording from the plate. The longer the junking time more is the shear strength.

12. Peel Adhesion test

It's the force to peel off an tenacious coating from a test substrate and is appertained to as peel adhesion. Molecular weight of polymer of glue, the quantum and nature of complements are the variables which controlled the peel adhesion parcels. A single tape recording on a pristine sword plate or a backing membrane of desire and later tape recording is pulled from the substrate at 180º angle, and the force necessary for tape recording removed is quantified.

13. Thumb method test

It' s qualitative test used for tenacious method property determination. The thumb is simply pressed on the tenacious and the relative method property is tasted.

14. Flatness test

Three longitudinal strips from each film are to be cut at different portions like one from the centre, other bone from left side, and another bone from right side. Length of every strip was taken and variation in length due to non-uniformity of flatness was taken by chancing percent condensation, 0 condensation being equal to 100 flatness.

15. Chance extension break test

Chance extension break is to be set up by observing the length at the point of break the chance extension can be calculated using the following formula.

Chance extension at Break (%) = (L1- L0)/ L0 × 100

Where

L_0 = original length of the sample

L_1 = Final length of the sample at breaking point (27).

TRANSDERMAL MARKET PRODUCT

The request for transdermal products has been in a significant upward trend that's likely to continue for the foreseeable future. An adding number of TDD products continue to deliver real remedial benefit to cases around the world. further than 35 TDD products have now been approved for trade in the US, and roughly 16 active constituents are approved for use in TDD products encyclopedically (28,29).

OPERATION

1. The best- dealing transdermal patch in the United States is the nicotine patch, which releases nicotine in controlled quantities to help in the conclusion of tobacco smoking.
2. Two opioid medicines that are used to offer round the-timepiece pain relief for cases with severe pain are generally specified in patch form Fentanyl (vended under the name Duragesic) and Buprenorphine (vended under the name Bu Trans).
3. Estrogen patches are sometimes specified to treat menopausal pattern as well as postmenopausal osteoporosis. Other transdermal patches for hormone delivery include the contraceptive patch (retailed as Ortho Evra or Evra).
4. Nitroglycerin patches are occasionally specified for the treatment of angina in lieu of sublingual capsules.
5. Theanti-hypertensive medicine Clonidine is available in transdermal patch form.
6. Transdermal form of the MAOI selegiline, came the first transdermal delivery agent for an antidepressant.
7. Transdermal delivery agent for the Attention deficiency Hyperactivity complaint (ADHD) .(30,31,32).

FACTORS AFFECTING

Skin condition

The complete skin itself is a hedge, but utmost agents similar as acids and alkali percolate the hedge cells and pass through the skin. utmost detergents disrupt the complex thick structure of the wanton sub caste detergents similar as methanol and chloroform strip down the lipid bit, creating artificial shunts through which medicine motes pass fluently (33).

Skin age

It can be observed that the grown-ups' as well as youthful bones ' skin is more passable than the old bones. but there is n't important dramatic difference. youthful bones parade poisonous goods due to the larger face area per unit body weight. therefore, strong steroids, boric acid and hexachlorophene have caused severe side-goods.

Physicochemical considerations

Hydration of skin

When the skin is impregnated with water, it swells apkins, softens the wrinkles on the skin and permeability increases for the motes of the medicine piercing through the skin (34).

Temperature and pH of the skin: The rate of penetration is different if the temperature is different and the diffusion coefficient decreases when the temperature dips; however proper clothing over the body does not allow large fluctuations in temperature and rates of penetration. Depending on the pH, unionized molecules pass easily through the lipid membrane, and weak acids and bases dissociate into varying degrees based upon

their pH and pKa or pKb values. Therefore, the unionized concentration of drug in applied phase will determine the effective membrane gradient, which is directly dependent upon its pH [34].

Environmental factors

Sunlight: Due to sunlight, the walls of blood vessels become thinner, resulting in bruising, with minimal trauma in the sun-exposed parts. Also, pigmentation, the most readily apparent sun-induced pigmentary change, is a freckle or solar lentigo [35].

Cold season: The winter months usually make your skin itchy and dry. The skin reacts by producing more oil to make up for the drying effects of the weather. A decent moisturizer will relieve symptoms of dry skin. Also, increasing water intake can keep your skin moisturized and glowing [35].

Air pollution: Dust can block pores and cause more bacteria on the face and the skin surface, both of which cause acne or spots, which influences drug delivery through the skin. Inhospitable chemical air pollutants that cannot be seen may disrupt the skin's natural defence mechanism, degrading the natural oils of the skin that usually lock in moisture in the skin and keep it pliable [35].

CONCLUSION:

A significant advancement in contemporary pharmaceutics, transdermal drug delivery systems bridge the gap between patient convenience, safety, and efficacy. TDDS offers an efficient substitute for oral and parenteral methods by avoiding hepatic first-pass metabolism and permitting controlled, prolonged drug release. Even though problems like poor drug permeability and possible skin irritation still exist, ongoing developments in formulation technology, penetration augmentation strategies, and polymer science are gradually getting past these obstacles. The therapeutic horizon of both new and existing drug molecules could be greatly expanded by TDDS, given the increasing number of transdermal medications on the market and the continuous research into innovative delivery systems. Transdermal technologies, which support accuracy, comfort, and better treatment results, are therefore a key component of future drug delivery schemes.

REFERENCE:

1.Tiwary AK, Sapra B, Jain S. Innovation in transdermal drug delivery: Formulation and techniques. Recent Pat Drug Deliv Formul 2007;1:23-36

2.Chong S, Fung HL, In: Hadgraft J, Guy RH, editors. Transdermal drug delivery. development issues and research initiatives. New York: Marcel Dekker; 1989. p. 135-54.

3.Singh A,Singh MP,Alam G,Patel R, Vishvakarma D, Datt N.Expanding opportunities for transdermal delivery systems;An overview, J Pharm Res 2011;4:1417-20.

4. Ansel HC, Allen LV and Popovich NG. Pharmaceutical dosage forms and drug delivery system. 7th ed. New York: Lipponcott Williams and Wilkins; 2002.

5. Patel RP, Baria AH. Formulation and evaluation consideration of transdermal drug delivery system. Int J Pharm Res 2011;3:1-9.

6. Kumar JA, Pullakandam N, Prabu SL, Gopal V. Transdermal drug delivery system: An overview. Int J Pharm Sci Rev Res 2010;3:49-54.

7. Jain NK. Advances in controlled and novel drug delivery. 1st ed. New Delhi: CBS Publishers and Distributors; 2001. p. 108-10.

8. Soni M, Kumar S, Gupta GD. Transdermal drug delivery: A novel approach to skin permeation. J Pharm Res 2009;2:1184-90.

9. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: Overcoming the skin’s barrier function. Pharm Sci Technol Today 2009;3:318-26.

10. Chandrashekhar NS, Shobha R. Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery. Indian J Pharm Sci 2008;70:94-5.

11. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharmaceutical Science and Technology Today 2000;3:318 - 326.

12. William AC, Barry BW. Penetration enhancer. Adv Drug Delivery 2004; 56:603-618.

SSaspects and molecular modeling of transdermal peptide flux enhancement by N-alkylazocylohepton.Int J Pharm 1991;76:37-47.

13.Hoogstrate AJ, Verhoef J, Brusee, Ijzerman AP, Spies F, Bodde HE. Kinetic, ultrastructural aspects and molecular modeling of transdermal peptide flux enhancement by N-alkylazocylohepton. Int J Pharm 1991; 76: 37-47.

14. Md. Intakhab Alam, Nawazish Alam, "Type, preparation, and evaluation of transdermal patch: A review." Research gate 2013 Vol. 2, Issue 4, and 2199-2233.

15. Darwhekar G, Jain Dk, Paditar Vk. Formulation and Evaluation of Transdermal Drug Delivery System of Clopidogrel Bisulfate. Asi. J. Pharmacy Life Sci. 2011; 1(3): 269-278.

16. Das, U. S., Pande K.H., an Overview of Diabetes Mellitus, World Journal of Pharmacy and Pharmaceutical Sciences. 2013; 2(1): 161-178.

17. 1. Jain, N. K., Controlled and Novel Drug Delivery, CBS Publishers, and Distributors, 2002, 107.

18. Chien, YW, Novel drug delivery systems, Drugs and the Pharmaceutical Sciences, Vol.50, Marcel Dekker, New York, NY;1992;797

19. Jain.N.K, Controlled and novel drug delivery, first edition, CBS publishers and distributors, New Delhi.1997

20.3M World Wide, 3M Drug deleviry system, Transdermal patches, www.3Mworldwide.com

21.Ryan D. Gordon, and Tim A. Peterson, transdermal drug delivery ,drug delivery technology,

22.Barry Bw, The Lpp Theory of Skin Penetration Enhancement. Maturitas. 1998; 29: 165–85.

23.Ghafourian T, Zandasrar P, Hamishekar H, Nokhodchi A, the Effect of Penetration Enhancers on Drug Delivery Through Skin: A Qsar Study. J Control Release.2004; 99: 113–25.

24. Montia D, Saettone Mf, Giannaccini B, Angeli Dg, Enhancement of Transdermal Penetration of Dapiprazole Through Hairless Mouse Skin. J Control Release.1995; 33: 71–7.

25. Bharadwaj S, Gupta Gd, Sharma Vk. Topical Gel: A Novel Approach for Drug Delivery. J Chem. Bio. Phy. Sci. 2012; 2(2): 856-867.

26. Sharma N, Parashar B, Sharma S, Mahajan U. Blooming Pharma Industry With Transdermal Drug Delivery System. Indo Global J Pharm. Sci. 2012; 2(3): 262-278.

27. Wade A, Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association; 1994: 362366.

28.Mitragotri S, Blank schtein D, Langer R. Transdermal drug delivery using lo frequency sonophoresis. Pharm Res. 1996:13(3):411-420.

29. Mitragotri S. Effect of therapeutic ultrasound on partition and diffusion coefficients in human stratum corneum. J Controlled Rel. 2001:71:23-29.

30. Jain, N. K., Controlled and Novel Drug Delivery, CBS Publishers, and Distributors, 2002, 107.

31. Chien, YW, Novel drug delivery systems, Drugs and the Pharmaceutical Sciences, Vol.50, Marcel Dekker, New York, NY;1992;797

32. Jain N.K, Controlled and novel drug delivery, first edition, CBS publishers and distributors, New Delhi.1997.

33. Singh MC, Naik AS, Sawant SD. Transdermal drug delivery systems with major emphasis on Transdermal Patches: A review. J Pharm Res 2010;3:2537-43.

34. Aulton ME. Aulton's Pharmaceutics The design and manufacture of medicine. 3rd ed. Churchill Livingstone: Elsevier; 2007. p. 567-8.

35. Jain NK. Controlled and Novel Drug Delivery. New Delhi: CBS Publishers and Distributors; 2002. p. 107

ACKNOWLEDGMENT

We sincerely expresses gratitude to the faculty members and mentors of the Department of Pharmaceutics for their continuous guidance, valuable suggestions, and encouragement throughout the preparation of this review paper. Their insightful feedback and expertise have been instrumental in shaping the understanding of transdermal drug delivery systems. Finally, heartfelt thanks are extended to friends and family for their constant support and motivation during the course of this work.